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Abstract
Background: Although an abundance of evidence has indicated that tumor-associated macrophages (TAMs) are
associated with a favorable prognosis in patients with colon cancer, it is still unknown how TAMs exert a protective
effect. This study examined whether TAMs are involved in hepatic metastasis of colon cancer.
Materials and methods: One hundred and sixty cases of pathologically-confirmed specimens were obtained from
colon carcinoma patients with TNM stage IIIB and IV between January 1997 and July 2004 at the Cancer Center of
Sun Yat-Sen University. The density of macrophages in the invasive front (CD68TFHotspot) was scored with an
immunohistochemical assay. The relationship between the CD68TFHotspot and the clinicopathologic parameters, the
potential of hepatic metastasis, and the 5-year survival rate were analyzed.
Results: TAMs were associated with the incidence of hepatic metastasis and the 5-year survival rate in patients
with colon cancers. Both univariate and multivariate analyses revealed that the CD68TFHotspot was independently
prognostic of survival. A higher 5-year survival rate among patients with stage IIIB after radical resection occurred
in patients with a higher macrophage infiltration in the invasive front (81.0%) than in those with a lower
macrophage infiltration (48.6%). Most importantly, the CD68TFHotspot was associated with both the potential of
hepatic metastasis and the interval between colon resection and the occurrence of hepatic metastasis.
Conclusion: This study showed evidence that TAMs infiltrated in the invasive front are associated with
improvement in both hepatic metastasis and overall survival in colon cancer, implying that TAMs have protective
potential in colon cancers and might serve as a novel therapeutic target.
Background
Colorectal cancer is the fourth leading cause of cancer
deaths worldwide. Of patients with colorectal cancer,
35%-55% will develop hepatic metastases at some time
during the course of their disease. Survival following
hepatic resection of colorectal metastasis now
approaches 35%-50%. However, approximately 65% of
patients will have a recurrence at 5 years. Identifying the
markers for hepatic metastasis would be helpful for the
early treatment of patients at high-risk of hepatic metas-
tasis [1-5].
In addition to clonal selection and the predetermined
metastatic potential of cancer cells, there is increasing evi-
dence indicating that the microenvironment modifies the
metastasis of cancer cells [6-9]. Cancer tissue is infiltrated
with stromal cells including macrophages. Tumor-asso-
ciated macrophages (TAMs) are not only abundant in
epithelial cancers, but also involved in cancer progression
[10-13]. Experimental data have indicated that ablation of
macrophage function or inhibition of macrophage infiltra-
tion into experimental tumors inhibits tumor growth and
metastases [14]. Additionally, gene array studies of diag-
nostic lymph node specimens in follicular lymphoma have
shown that genes associated with a strong ‘macrophage’
signature are associated with a poorer prognosis, indepen-
dent of clinical variables or of gene expression of the
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progression by induction of chronic inflammation, matrix
remodeling, tumor invasion, intravasation, angiogenesis,
and seeding at distant sites [13]. In contrast, recruitment
of TAMs also contributes to the development of an adap-
tive immune response against cancer. TAMs contribute to
the balance between antigen availability and clearance
through phagocytosis and subsequent degradation of
senescent or apoptotic cells. The role of TAMs is essential
for triggering, instructing, and terminating the adaptive
immune response [16]. The clinical evidence regarding the
relationship between TAMsa n dt u m o rp r o g r e s s i o ni s
tumor type-dependent. The higher density of TAMs is
associated with a poorer prognosis in leiomyosarcomas,
melanomas, gliomas, and cancers of the breast, bladder,
rectum, and endometrium, but the prognosis is favorable
in nasopharyngeal, gastric, and ovarian cancers [17-28].
Additionally, in liver, lung, and prostate cancers, the role
of TAMs on prognosis is controversial [29-35].
With respect to colorectal carcinomas, clinical data
indicate that TAMs are associated with a favorable
prognosis [36-39]. However, these studies have not indi-
cated the sites at which TAMs show a protective effect.
Because macrophages modify tumor invasion, intravasa-
tion, and angiogenesis, whether or not TAMs interfere
with hepatic metastasis of colon cancer was determined
in the current study.
Materials and methods
Materials
One hundred and sixty cases of pathologically-con-
firmed specimens were obtained from colon carcinoma
patients with TNM stage IIIB and IV between January
1997 and July 2004 at the Cancer Center of Sun Yat-
Sen University. Patients with stage IV colon carcinoma
who were enrolled in this study had primary colon can-
cer with synchronous liver metastasis, irrespective of
extra-hepatic involvement. Ninety-eight patients with
stage IIIB colon carcinoma underwent radical surgery,
while 62 patients with stage IV colon carcinoma under-
went palliative colon resection with or without resection
of hepatic lesions. None of the patients had undergone
either chemotherapy or radiotherapy before the collec-
tion of the samples. The histopathologic characteristics
of the colon carcinoma tissue specimens were confirmed
by blinded review of the original pathology slides. The
TNM classification system of the UICC (edition 6) was
used for clinical staging, and the World Health Organi-
zation classification was used for pathologic grading.
The study was conducted in accordance with the Hel-
sinki Declaration and approved by the Ethics Committee
of our institution. Patients were informed of the investi-
gational nature of the study and provided their written
informed consent.
Follow-up of stage IIIB patients and post-operative
treatment
Clinical follow-up was only provided to stage IIIB
patients, as patients with stage IV in this study were a
group with high heterogeneity, including solitary or
multiple liver metastases, and liver only or other sites
involved with metastases; these variables affected the
treatment protocols and eventually the response rate
and prognosis. Ninety-eight patients with stage IIIB
c o l o nc a r c i n o m aw e r eo b s e r v e do na ne v e r y - 3 - m o n t h
basis during the 1
st year, once every 6 months in the 2
nd
year, and by telephone or mail communication once
every year thereafter for a total of 5 years. If recurrence
or metastasis occurred, 5-FU-based chemotherapy was
administered according to the NCCN guidelines [40].
Overall survival (OS) was defined as the time from sur-
gery to death, or was censored at the last known alive
data. Liver metastasis-free survival (LMFS) was defined
as the time from surgery to liver metastasis.
Immunohistochemistry
The specimens were fixed in formaldehyde and
embedded in paraffin. Only blocks containing the tumor
front were evaluated. Tissue sections of 5-μmt h i c k n e s s
were cut, dried, deparaffinized, and rehydrated in a ser-
ies of alcohols and xylene before antigen retrieval by
pressure cooker treatment in citrate buffer (pH 6.0) for
3 minutes. After that, we performed endogenous peroxi-
dase blocking through hydrogen peroxide incubation.
Mouse anti-human CD68 monoclonal antibody (mAb)
(PG-M1; DakoCytomation, Glostrup, Denmark) at a
1:300 dilution was used. Immunostaining for CD68 was
performed using EnVision + Dual Link Kit (Dako Cyto-
mation) according to the manufacturer’si n s t r u c t i o n s .
The development was performed with a substrate-chro-
mogen solution (3,3’-diaminobenzidine dihydrochloride
[DAB]) for 3-5 minutes (brown reaction product). Sec-
tions were then counterstained with hematoxylin and
mounted in non-aqueous mounting medium.
To analyze macrophage phenotypes, antibodies were
stained as follows: 1) IL-12 mAb (1:30, catalog number:
s c - 7 4 1 4 7 ,m o u s eI g G 1 ,S a n t aC r u zb i o t e c h n o l o g y ,C A ,
USA), 2) human leukocyte antigen (HLA)-DR mAb
(1:300, catalog number: ZM-0136, mouse IgG2b, Zhong-
shan Goldenbridge biotechnology, Beijing, China), 3) IL-
10 Ab (1:400, ab34843, rabbit polyclonal Ab, Abcam), 4)
transforming growth factor beta1 (TGF-b1) mAb (1:800,
catalog number: sc-146, rabbit IgG, Santa Cruz biotech-
nology, CA, USA).
CD68 evaluation
Referring to Forssell’s [36] scoring system, CD68 immu-
nostaining along the tumor front was evaluated over the
whole section (7-10 fields per section) and tumors
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CD68-positive cells was considerably above the average
level of CD68-positive cells was defined as CD68 hot-
spots (CD68TFHotspot) [36]. All sections were evaluated
far from necrosis areas and H.E. staining was reviewed
in case of uncertainty. The CD68TFHotspot of the two
highest view fields measured at ×200 magnification was
semi-quantitatively graded as no/weak (grade 1), moder-
ate (grade 2), strong/robust (grade 3), and massive infil-
tration (grade 4). Tumors classified as 1 included
completely negative specimens, as well as specimens
containing some scattered CD68-positive cells along the
tumor margin. Tumors were classified as 2 when CD68
staining was continuous along the tumor margin, but
was not extended from the tumor front more than one
cell layer on average. CD68 staining that, on average,
extended 2-3 cell layers from the tumor margin over the
whole section was classified as 3, whereas to be classi-
fied as 4, CD68 staining extended several cell layers
from the tumor margin in all fields. Each section was
scored independently by two independent observers.
Interobserver agreements for the CD68TFHotspot were
81%. Disagreements were re-evaluated until a consensus
decision was made.
Statistical analysis
The relationship between the various clinicopathologic
characteristics and the CD68TFHotspot parameters were
compared and analyzed using c
2 tests, likelihood ratio,
and linear-by-linear association, as appropriate. The
cumulative survival time was computed using the
Kaplan-Meier method and compared by the log-rank
test. Univariate and multivariate analyses were based on
the Cox proportional hazards regression model. A two-
tailed P < 0.05 was considered to be statistically signifi-
cant. All statistical analyses were performed using SPSS
13.0 software for Windows (SPSS Inc., Chicago, IL,
USA).
Results
CD68 expression
TAMs were stained brown in the cytoplasm. The major-
ity of CD68-positive cells were located in the stroma,
and in particular, along the invasive front. CD68-positive
cells were mostly in apparent direct contact with or
immediately adjacent to tumor cells lining the invasive
front. Although most areas along the invasive front dis-
played a fairly homogeneous CD68+ infiltration pattern,
there were also tumors containing small areas that
showed CD68 infiltration considerably above the average
grade (CD68TFHotspot). The CD68TFHotspot was semi-
quantitatively graded from 1-4 (Fig. 1).
To identify the phenotype of TAMs, a group of conse-
cutive sections was used to stain with CD68, HLA-DR,
TGF-b1, IL-10, and IL-12. TAMs were popularly stained
with HLA-DR, IL-10, sporadically stained with TGF-b1,
negatively stained with IL-12, indicating that TAMs
were activated without classic M1 or M2 phenotype
(Fig. 2).
Relationship between CD68TFHotspot and clinicopathologic
characteristics
We used the c
2 test to assess the relationship between
the TAMs and clinicopathologic characteristics. The
results showed that the CD68TFHotspot was inversely
correlated with TNM stage, the presence of hepatic
metastasis, and pathologic classification (Table 1). When
hepatic metastasis status was cut into the following
three patterns, the CD68TFHotspot was also highly corre-
lated with the status of hepatic metastasis: no hepatic
metastasis (stage IIIB colon cancer without liver metas-
tasis within 5 years of follow-up), metachronous hepatic
metastasis (stage IIIB colon cancer with liver metastasis
within 5 years of follow-up), and synchronous liver
metastasis (stage IV colon cancer with liver metastasis
before palliative surgery).
Survival analyses
By the end of the 5-year follow-up, 68 of patients with
stage IIIB colon carcinoma were alive, thus the 5-year
survival rate was 69.4%. Based on univariate analysis,
including all stage IIIB patients applicable to survival
analyses (n = 98), age, gender, tumor invasive depth,
pathologic grade, and growth pattern showed no prog-
nostic significance for OS and LMFS (Table 2). In con-
trast, the sites of primary tumors, pathologic
classification, and hepatic metastasis were predictors for
OS. The CD68TFHotspot was highly correlated to OS (P
= 0.001; log rank test; data not shown), but not LMFS
(P = 0.221; log rank test; data not shown).
For further analysis, the grade data of the CD68TFHot-
spot were divided into 2 groups (grade 1 and 2 versus 3
and 4) according to Forssell’s protocol [36]. Therefore,
cases were regrouped into CD68TFHotspot high (3 and 4)
versus CD68TFHotspot low (1 and 2) macrophage infiltra-
tion. Kaplan-Meier survival curves were then plotted to
further investigate the association with OS. The log-
rank statistic was used to compare survival rates. There
was a positive association between the CD68TFHotspot
group and both OS (P < 0.001) and LMFS (P = 0.037;
Fig. 3).
Multivariate Cox proportional hazards analysis
Whether or not the CD68TFHotspot group could serve as
an independent predictor of OS and LMFS was ana-
lyzed. A multivariate Cox proportional hazards analysis
was performed, including gender, age, sites of primary
tumors, invasive depth, grade, pathologic classifications,
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Page 3 of 9Figure 1 Representative pictures of CD68TFHotspot in colon cancer patients (200× magnification). Different grades of macrophage
infiltration along the tumor front were examined with immunohistochemical assay: A, no/low, B, moderate, C, high, and D, massive. Arrows
point at tumor front.
Figure 2 Representative images of macrophage phenotypes in colon cancer on consecutive sections. Arrows point at tumor front.
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groups. In stage IIIB colon cancers, the high
CD68TFHotspot group had a significantly lower risk for
OS (hazard ratio [HR], 0.433; 95% confidence interval
[CI], 0.194-0.966) and LMFS (HR, 0.265; 95% CI, 0.078-
0.900) than did the low CD68TFHotspot group. Liver
metastasis (HR, 8.144; 95% CI, 3.276-20.250) was an
independent prognostic factor for OS. Additionally,
patients with left colon cancer were prone to have a
longer OS, whereas pathologic classification was not
associated with OS (Table 3).
Discussion
By analyzing the relationship between the density of
TAMs and the potential of hepatic metastasis and survi-
val, this study showed that a higher density of macro-
phages in the invasive front of colon cancer was
associated with a higher 5-year survival rate. Most
importantly, the CD68TFHotspot was associated with
both the incidence of hepatic metastasis and the interval
between colon resection and the occurrence of hepatic
metastasis.
In contrast to other solid tumors, such as breast can-
cer, most studies have shown that TAMs, especially IL-
12-positive TAMs, inhibit the progression of colon can-
cers [36-39,41-44]. For example, in Forssell’s study [36]
the higher macrophage infiltration along the tumor
front correlated with improved survival in colon cancer
compared to rectal cancer. In the current study, the Cox
model indicated that the CD68TFHotspot was indepen-
dently prognostic. A higher 5-year survival rate after
radical resection occurred in patients with a higher
macrophage infiltration in the invasive front (81.0%)
than in those with a lower macrophage infiltration
(48.6%), which is in agreement with the previous studies
[36-39].
The mechanisms behind the antitumor effects of
TAMs have not been fully elucidated and could poten-
tially be ascribed to the M1 phenotype, which is in part
controlled by the CD4+T cells and the death of cancer
cells [45-47]. TAMs with the M1 phenotype are charac-
terized by a high capacity to present antigen, high IL-12
and IL-23 production, and high production of toxic
intermediates, such as nitric oxide and reactive oxygen
intermediates. Thus, TAMs with the M1 phenotype are
generally considered potent effector cells which kill
tumor cells [48-51]. In fact, TAMs showed a spectrum
from M1 to M2 phenotypes in murine colon adenocar-
cinoma tumors [52]. This study showed that TAMs
expressed with HLA-DR and IL-10 rather than TGF-b1
and IL-12, consistent with the previous observation
[52]. Although an abundance of evidence relevant to the
molecular mechanisms underlying the anti-tumor effect
of macrophages has been documented, it is still
unknown how TAMs exert a protective effect, except
that one recent study indicated that TAMs reduce the
development of peritoneal colorectal carcinoma metas-
tases [36-39,41-44,53]. The current study analyzed the
relationship between the infiltration of TAMs and hepa-
tic metastasis. The results showed that a higher density
of TAMs in the invasive front was associated with
lower synchronous and metachronous hepatic metas-
tases. Since hepatic metastasis of colon cancer is a key
prognostic factor, this study might partly explain the
Table 1 Correlation between CD68TFHotspot and
clinicopathologic characteristics.
Variable CD68TFHotspot P value
-/+ + ++ +++
123 4
Gender
Male 23 21 37 13 0.939
Female 15 13 27 11
Age (years)
< 60 22 17 26 15 0.195
≥ 60 16 17 38 9
Sites of primary tumors
Left 25 14 40 16 0.107
Right 13 20 24 8
TNM stages
IIIB 17 18 46 17 0.025*
IV 21 16 18 7
Invasive depth
T3 31 30 53 17 0.422
a
T4 7 4 11 7
Hepatic metastasis(1)
No 13 14 42 16 0.004*
Yes 25 20 22 8
Hepatic metastasis(2)
No 13 14 42 16 0.001*
b
Metachronous 4 4 4 1
Synchronous 21 16 18 7
Grade
G1 1 1 1 0 0.124
b
G2 23 21 48 21
G3 14 11 14 2
G4 0 1 1 1
Pathologic classification
Papillary + tubular 28 25 57 23 0.022*
a
Mucoid + signet ring 10 9 7 1
Growth pattern
Pushing 19 8 18 8 0.071
Infiltrating 19 26 46 16
*: p < 0.05. a: Likelihood ratio. b: Exact linear-by-linear association test.
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nosis of patients with colon cancer.
The molecular mechanisms underlying hepatic metas-
tasis of colon cancers is poorly understood. Traditional
clinicopathologic indices for hepatic metastasis of color-
ectal cancer, which include the depth of invasion, the
presence of venous invasion, and lymph node metastasis,
have only limited prognostic value [54]. Although multi-
ple markers, such as CD10, CD44, VEGF, TGF-a,h a v e
been shown to be correlated with hepatic metastasis, the
predictive efficacy of these markers is still unclear
[55-60]. In the current study, a higher density of TAMs
in the invasive front was associated with lower synchro-
nous hepatic metastasis and lower metachronous hepatic
metastasis, showing that the immune microenvironment
of the primary tumor modifies the metastatic potential
of colon cancer, and the function of TAMs is change-
able in different tumor microenvironment [61].
Most immune cells, such as CD45RO+T cells, CD3
+T cells, NK cells, TAMs, and even Treg cells, have
shown a protective effect when infiltrated into colon
cancer tissue [62-67]. Additionally, an autoimmune
response is associated with the efficacy of biochem-
otherapy (GOLFIG regimen) for colon cancer [68,69].
The current study has given additional evidence that
macrophage infiltration is involved in the inhibition of
hepatic metastasis. These data indicate that colon can-
cer is an immunogenic tumor. Therefore, more
Table 2 Univariate analyses of factors associated with OS and LMFS.
Variable OS (n = 98) LMFS (n = 98)
HR, (95% CI) P value HR, (95% CI) P value
Gender (female vs. male) 1.157 (0.562-2.381) 0.693 0.416 (0.114-1.510) 0.182
Age (< 60 y vs. ≥ 60 y) 0.732 (0.352-1.519) 0.402 0.704 (0.230-2.153) 0.538
Invasive depth (T4 vs. T3) 1.023 (0.392-2.674) 0.962 0.902 (0.200-4.068) 0.893
Sites of primary tumors (right vs. left) 2.271 (1.093-4.717) 0.028* 0.815 (0.267-2.491) 0.720
Grade (G3 vs. G2 vs. G1) 1.519 (0.715-3.224) 0.277 1.036 (0.324-3.311) 0.953
Pathologic classification (mucoid + signet ring vs. papillary + tubular) 2.415 (1.129-5.168) 0.023* 1.148 (0.316-4.171) 0.834
Growth pattern (infiltrating vs. pushing) 0.817 (0.389-1.718) 0.595 2.709 (0.600-12.223) 0.195
CD68TFHotspot (4 vs. 3 vs. 2 vs.1) 0.568 (0.393-0.822) 0.003* 0.594 (0.344-1.025) 0.061
CD68TFHotspot group (high vs. low) 0.288 (0.139-0.600) 0.001* 0.324 (0.106-0.991) 0.048*
Hepatic metastasis (yes vs. no) 5.852 (2.737-12.511) 0.000** NA NA
Univariate analysis, Cox proportional hazards regression model. Abbreviations: HR, hazard ratio; CI, confidence interval; NA, not assessment. *: p<0 . 0 5 ;* * :p<
0.001.
Figure 3 Kaplan–Meier analysis of overall survival (A) and liver metastasis-free survival (B) for CD68TFHotspot group. The patients with a
higher CD68TFHotspot group (solid lines) were associated with longer 5-year overall survival and liver metastasis-free survival than those with a
lower CD68TFHotspot group (dashed lines).
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response in an effort to improve conventional therapy
for colon cancer [70].
Additionally, our study main aim is to find if there any
relationship between macrophages and liver metastasis
in colon cancer which was cut into the following three
patterns: no hepatic metastasis, metachronous and syn-
chronous liver metastasis. We decided to choose single
stage IIIB colon cancer which is the biggest group in
our center colon resource database to avoid the influ-
ence of different stages factor on relationship between
macrophages and liver metastasis. Although this consti-
tution minimized confounding factors, it cannot com-
pletely represent ordinary setup, so our results, and as
such, should be viewed with some caution.
Conclusion
This study demonstrated that TAMs infiltrated in the
invasive front are associated with improvement in both
hepatic metastasis and OS in colon cancer, implying
that TAMs have protective potential in colon cancers
and might serve as a novel therapeutic target.
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